JP2014531020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531020A5 JP2014531020A5 JP2014533426A JP2014533426A JP2014531020A5 JP 2014531020 A5 JP2014531020 A5 JP 2014531020A5 JP 2014533426 A JP2014533426 A JP 2014533426A JP 2014533426 A JP2014533426 A JP 2014533426A JP 2014531020 A5 JP2014531020 A5 JP 2014531020A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- bin1
- seq
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541539P | 2011-09-30 | 2011-09-30 | |
| US61/541,539 | 2011-09-30 | ||
| PCT/US2012/058051 WO2013049666A1 (en) | 2011-09-30 | 2012-09-28 | Bin1 expression as a marker of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531020A JP2014531020A (ja) | 2014-11-20 |
| JP2014531020A5 true JP2014531020A5 (enExample) | 2015-11-05 |
| JP6170925B2 JP6170925B2 (ja) | 2017-07-26 |
Family
ID=47023105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533426A Active JP6170925B2 (ja) | 2011-09-30 | 2012-09-28 | 癌のマーカーとしてのｂｉｎ１の発現 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9846159B2 (enExample) |
| EP (1) | EP2761298B1 (enExample) |
| JP (1) | JP6170925B2 (enExample) |
| CA (1) | CA2850178C (enExample) |
| WO (1) | WO2013049666A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2850178C (en) | 2011-09-30 | 2020-02-25 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| HK1246394A1 (zh) | 2015-03-02 | 2018-09-07 | Sarcotein Diagnostics Llc | 13+/17+bin1表达作为心脏病症的标记 |
| GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| WO2017176835A2 (en) * | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| KR20250047324A (ko) | 2017-08-07 | 2025-04-03 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
| CN113122634B (zh) * | 2020-01-14 | 2026-03-10 | 江苏鹍远生物科技股份有限公司 | 检测dna甲基化的试剂及用途 |
| CN112794900B (zh) * | 2020-12-31 | 2022-10-25 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| US6048702A (en) | 1995-05-05 | 2000-04-11 | The Wistar Institute Of Anatomy And Biology | Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor |
| US6410237B1 (en) | 1997-07-18 | 2002-06-25 | Board Of Trustees Operating Michigan State University | DNA encoding canine von Willebrand factor and methods of use |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| AU5632300A (en) | 1999-07-07 | 2001-01-30 | Regeneron Pharmaceuticals, Inc. | Methods of inhibiting muscle atrophy |
| US6831063B1 (en) | 1999-08-31 | 2004-12-14 | The Wistar Institute Of Anatomy And Biology | Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor |
| US6461828B1 (en) | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
| US20040106954A1 (en) | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
| CA2527285A1 (en) | 2003-05-28 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US20040241764A1 (en) | 2003-06-02 | 2004-12-02 | Uri Galili | Early detection of recipient's immune response against heart transplant |
| WO2005037230A2 (en) | 2003-10-14 | 2005-04-28 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating heart failure |
| WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| US20060003959A1 (en) | 2004-06-10 | 2006-01-05 | Steven Burden | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same |
| WO2006122295A2 (en) | 2005-05-11 | 2006-11-16 | Expression Diagnostics, Inc. | Methods of monitoring functional status of transplants using gene panels |
| WO2007130549A1 (en) | 2006-05-02 | 2007-11-15 | Govt.Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibody microarray |
| WO2008008846A2 (en) | 2006-07-11 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential expression of molecules associated with intra-cerebral hemorrhage |
| WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| US20120094300A1 (en) | 2009-04-24 | 2012-04-19 | Robin Shaw | Bin1 as a Prognostic Marker in Cardiovascular Disease |
| US20110217713A1 (en) * | 2010-03-05 | 2011-09-08 | On-Q-ity | Biomarkers For The Identification, Monitoring, And Treatment Of Non-Small Cell Lung Cancer (NSCLC) |
| US8999659B2 (en) | 2010-10-20 | 2015-04-07 | The Regents Of The University Of California | Body fluid BIN1 as a marker of cardiac health |
| EP2638403B1 (en) | 2010-11-09 | 2017-03-22 | Sarcotein Diagnostics LLC | Bin1 expression as a marker of skeletal muscle mass and neurological conditions |
| CA2850178C (en) | 2011-09-30 | 2020-02-25 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| HK1246394A1 (zh) | 2015-03-02 | 2018-09-07 | Sarcotein Diagnostics Llc | 13+/17+bin1表达作为心脏病症的标记 |
-
2012
- 2012-09-28 CA CA2850178A patent/CA2850178C/en active Active
- 2012-09-28 JP JP2014533426A patent/JP6170925B2/ja active Active
- 2012-09-28 WO PCT/US2012/058051 patent/WO2013049666A1/en not_active Ceased
- 2012-09-28 US US14/348,269 patent/US9846159B2/en active Active
- 2012-09-28 EP EP12773186.7A patent/EP2761298B1/en active Active
-
2017
- 2017-11-30 US US15/827,568 patent/US10928396B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | CircRNA ciRS-7: a novel oncogene in multiple cancers | |
| Gul et al. | Adjuvant therapy in renal cell carcinoma | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Zinger et al. | Cancer and aging-the inflammatory connection | |
| Ezzoukhry et al. | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib | |
| Maierthaler et al. | Plasma miR‐122 and miR‐200 family are prognostic markers in colorectal cancer | |
| Huang et al. | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area | |
| JP2018508593A5 (enExample) | ||
| EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
| EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
| JP2016020389A5 (enExample) | ||
| NO20092604L (no) | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. | |
| JP2013506675A5 (enExample) | ||
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| Rostila et al. | Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure | |
| EA201390740A1 (ru) | Способ лечения с использованием ингибитора braf | |
| BR102012006063A8 (pt) | Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo | |
| JP2013539468A5 (enExample) | ||
| Crnkovic et al. | NPY/Y1 receptor‐mediated vasoconstrictory and proliferative effects in pulmonary hypertension | |
| JP2015506944A5 (enExample) | ||
| EA201201373A1 (ru) | Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток | |
| JP2015508063A5 (enExample) | ||
| JP2016539083A5 (enExample) | ||
| JP2019512695A5 (enExample) |